KPTI — Karyopharm Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $136.26m
- $248.22m
- $146.03m
- 36
- 43
- 59
- 43
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -200 | -196 | -124 | -165 | -143 |
Depreciation | |||||
Non-Cash Items | 21.1 | 33.7 | 39.4 | 35.1 | 18.4 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -13.3 | 1.34 | -23.2 | -20 | 31.4 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -191 | -160 | -107 | -150 | -92.7 |
Capital Expenditures | -0.206 | -0.145 | -0.212 | -0.118 | 0 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 78.7 | -53.5 | 142 | -104 | 7.94 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 78.5 | -53.7 | 142 | -104 | 7.94 |
Financing Cash Flow Items | — | — | 60 | 0 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 124 | 172 | 73.6 | 194 | 1.12 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 12 | -41.6 | 108 | -60.6 | -83.7 |